Business Context and Reporting Period
This Form 8-K, dated November 1, 2024, is filed by Adagio Medical Holdings, Inc. (ADGM), an emerging growth company incorporated in Delaware. The report addresses a material accounting error identified during the preparation of the Company's unaudited condensed consolidated financial statements for the nine months ended September 30, 2024. The filing relates to the Company's recent business combination with Adagio Medical, Inc. (Adagio), which closed on July 31, 2024.
Key Financial Metrics and Material Changes
The filing does not provide specific revenue, profit, cash flow, or liquidity figures for the current period. Instead, it discloses a material misstatement in previously issued financial statements for Adagio covering the following periods:
- Fiscal year ended December 31, 2023 (Audited).
- Three months ended March 31, 2024 and 2023 (Unaudited).
- Six months ended June 30, 2024 and 2023 (Unaudited).
Material Change: The Company identified an error in the recording of accrued interest within "Convertible notes payables, current" and "Other accrued liabilities." This resulted in an overstatement of accrued interest. Consequently, the previously issued financial statements for these periods are no longer reliable and must be restated. The restatement will be included in Amendment No. 2 to the Business Combination Super 8-K.
Internal Controls, Risks, and Remediation
Material Weakness: Management identified a material weakness in internal control over financial reporting and disclosure controls and procedures as of December 31, 2023, March 31, 2024, and June 30, 2024. This weakness stems from inadequate design and operation of management's review controls over valuation reports prepared by third-party specialists regarding certain debt and equity instruments.
Remediation Plan: Management is implementing the following measures:
- Additional review of third-party valuation reports used for debt and equity accounting.
- Additional review of manual journal entries based on externally generated reports and agreements.
- Enhanced oversight controls on work performed by third-party specialists.
Outlook and Guidance: The filing contains no specific financial guidance or outlook. It includes standard forward-looking statement disclaimers noting that actual results may differ materially from projections due to various risks and uncertainties.
Investor Verification Checklist
- Verify the specific dollar amount of the accrued interest overstatement once Amendment No. 2 to the Business Combination Super 8-K is filed.
- Monitor the upcoming Form 10-Q for the period ended September 30, 2024, for detailed specifics on the material weakness and the status of remediation efforts.
- Review the restated financial statements to understand the impact on Adagio's historical debt obligations and liabilities.
- Confirm that the restatement does not impact the pro forma condensed combined financial information previously presented for the Relevant Periods.